Organic Cation Transporter 2

Organic cation transporter consisting of twelve transmembrane domains and expressed primarily in the kidney. It transports a wide range of metabolites, drugs, and neurotransmitters from the blood to the KIDNEY TUBULES, including DOPAMINE; SEROTONIN; CHOLINE; and CISPLATIN.

Also Known As:

Networked: 52 relevant articles (2 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kamoshida, Shingo: 4 articles (01/2015 - 01/2014)
2.	Müller, Fabian: 3 articles (12/2020 - 07/2013)
3.	Naka, Ayano: 3 articles (01/2015 - 01/2014)
4.	Takeda, Risa: 3 articles (01/2015 - 01/2014)
5.	Gai, Zhibo: 2 articles (01/2021 - 01/2018)
6.	Kullak-Ublick, Gerd A: 2 articles (01/2021 - 01/2018)
7.	Visentin, Michele: 2 articles (01/2021 - 01/2018)
8.	Ebner, Thomas: 2 articles (12/2020 - 11/2020)
9.	Fromm, Martin F: 2 articles (12/2020 - 07/2013)
10.	Ishiguro, Naoki: 2 articles (12/2020 - 11/2020)

Related Diseases

1.	Colorectal Neoplasms (Colorectal Cancer) 01/01/2014 - "High expression of organic anion transporter 2 and organic cation transporter 2 is an independent predictor of good outcomes in patients with metastatic colorectal cancer treated with FOLFOX-based chemotherapy." 01/01/2014 - "Organic cation transporter 2 and tumor budding as independent prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy."
2.	Cardiotoxicity 01/01/2021 - "The most common problems produced by these interactions are related to cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest), increased exposure of cytochrome P450 2D6 (CYP2D6) substrates, or reduced renal clearance of organic cation transporter 2 (OCT2) substrates and include hypertensive crisis, increased risk of bleeding, myopathy, and/or rhabdomyolysis. "
3.	Torsades de Pointes (Torsade de Pointes) 01/01/2021 - "The most common problems produced by these interactions are related to cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest), increased exposure of cytochrome P450 2D6 (CYP2D6) substrates, or reduced renal clearance of organic cation transporter 2 (OCT2) substrates and include hypertensive crisis, increased risk of bleeding, myopathy, and/or rhabdomyolysis. "
4.	Rhabdomyolysis 01/01/2021 - "The most common problems produced by these interactions are related to cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest), increased exposure of cytochrome P450 2D6 (CYP2D6) substrates, or reduced renal clearance of organic cation transporter 2 (OCT2) substrates and include hypertensive crisis, increased risk of bleeding, myopathy, and/or rhabdomyolysis. "
5.	Muscular Diseases (Myopathy) 01/01/2021 - "The most common problems produced by these interactions are related to cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest), increased exposure of cytochrome P450 2D6 (CYP2D6) substrates, or reduced renal clearance of organic cation transporter 2 (OCT2) substrates and include hypertensive crisis, increased risk of bleeding, myopathy, and/or rhabdomyolysis. "

Related Drugs and Biologics

1.	Organic Anion Transporters
2.	Cytochrome P-450 CYP2D6 (CYP2D6)
3.	Proteins (Proteins, Gene)
4.	Member 1 Subfamily B ATP Binding Cassette Transporter
5.	Peptides (Polypeptides)
6.	Anions
7.	Metformin (Glucophage)
8.	Cisplatin (Platino)
9.	Platinum
10.	Carnitine (L-Carnitine)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Neoadjuvant Therapy